

MAP Pharmaceuticals, Inc.  
Form 8-K  
May 11, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 11, 2010**

**MAP PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-33719**  
**(Commission File Number)**

**20-0507047**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K

**2400 Bayshore Parkway, Suite 200, Mountain**

**View, CA**  
(Address of Principal Executive Offices)

**94043**  
(Zip Code)

**Registrant's telephone number, including area code: (650) 386-3100**

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

In a press release issued on May 11, 2010, MAP Pharmaceuticals, Inc. (the Company) provided an update on the Phase 3 development program for its LEVADEX product candidate for the potential treatment of acute migraine. The Company announced that it currently expects to file a New Drug Application ( NDA ) for LEVADEX with the United States Food and Drug Administration during the first half of 2011. The Company also announced that it will conduct a QT clinical trial, to evaluate whether LEVADEX has an effect on QT interval as measured by electrocardiogram, in support of the NDA. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of MAP Pharmaceuticals, Inc., dated May 11, 2010

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 11, 2010

**MAP PHARMACEUTICALS, INC.**

By: /s/ CHARLENE A. FRIEDMAN  
Name: **Charlene A. Friedman**  
Title: **Vice President, General Counsel and Secretary**

**INDEX TO EXHIBITS FILED WITH  
THE CURRENT REPORT ON FORM 8-K DATED MAY 11, 2010**

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release of MAP Pharmaceuticals, Inc., dated May 11, 2010